TY - JOUR T1 - Clinical profile of MDR-TB patients and their early response to DOTS PLUS: An Indian perspective JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P2800 AU - Abhay Javia AU - Deval Mehta AU - Firoz Ganchi AU - Bhupandra Rathod AU - Kalpesh Chopada AU - Milan Bhanderi Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P2800.abstract N2 - Background:The emergence MDR-TB is an obstacle to effective TB control in IndiaAim:to analyze the MDR TB patients(Pt) & to evaluate their response to DOTS PLUSMethods: A prospective cohort study of 58 MDR-TB Pts. Pt's detailed demographic data recorded & put on DOTS PLUS.Clinical evaluation,sputum smear,culture & DST at the end of 3,4,5,6 and 9 month were done to monitor progress during treatment. Treatment outcomes were noted at the end of initiation phase (IP)Results:MDR-TB were common in males (M:F=3:2),in age group 18-35 yrs(64%),in lower socioeconomic class(88%),in Pts with BMI <18.5(89% M,96% F),in rural areas(48%),with bilateral(85%) & cavitory(67%) lesion on CXR.Commonest symptoms were cough(100%),fever(95%) & weight loss(60%). Associated with DM(8.6%) & HIV(5.2%).High grade sputum & culture positivity (+2 & +3) were more prevalent(60% & 69% respectively). 85% had resistance to both H & R. End IP smear & culture conversion rate was 72.4% and 56.9% respectively while 15.5% showed smear conversion but culture non-conversion. Mean smear & culture conversion time was 3.4 & 4.12 months respectively. Low smear & culture conversion rate was seen in Pts with H& R resistance,bilateral & cavitory lesions on CXR and initial high grade smear & culture positivity. 6 Pts(10.3%) died and 4 Pts(6.9%) defaulted during IP. 33% Pts had ADR, the commonest being GI disturbance(42%),hearing loss(32%) & psychiatric disturbance(16%)Conclusion:Early diagnosis & treatment of MDR-TB is essential. Resistance to both H & R,bilateral & cavitory lesion in CXR,high grade initial smear & culture positivity,low BMI and DM is associated with poor outcome. We will continue our study till completion of treatment. ER -